• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

SSRIs are a focus of a new Trump executive order that installs Robert F. Kennedy Jr.'s 'Make America Healthy Again' commission. Here's what they do.

Health care startup Knownwell on Monday opened six clinics in greater Chicago that focus on weight loss management for adults ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...